Tetraphase submits NDA for eravacycline to treat cIAIs

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) submitted an NDA to FDA for IV eravacycline (TP-434) to treat complicated intra-abdominal infections (cIAIs). The submission is based on the Phase III IGNITE1 and IGNITE4 trials (see BioCentury, Dec. 22, 2014; July 27, 2015; & July 27, 2017)...